Ditchcarbon
  • Customers
  1. Organizations
  2. Cansino Biologics
Public Profile
Pharmaceutical Preparation Manufacturing
CN
updated 10 days ago

Cansino Biologics

Company website

Cansino Biologics Inc., commonly referred to as Cansino, is a prominent biopharmaceutical company headquartered in China (CN). Founded in 2009, the company has established itself as a leader in the development of innovative vaccines and biologics, with a strong focus on addressing global health challenges. Cansino operates primarily in the fields of vaccine research and development, particularly in the areas of infectious diseases and oncology. The company gained significant recognition for its pioneering work on the Ad5-nCoV vaccine, which was one of the first COVID-19 vaccines to receive emergency use authorisation. Cansino's unique adenoviral vector platform sets it apart in the industry, enabling rapid development and deployment of vaccines. With a robust pipeline and strategic partnerships, Cansino Biologics continues to solidify its position as a key player in the global biopharmaceutical landscape.

DitchCarbon Score

How does Cansino Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

37

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Cansino Biologics's score of 37 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.

62%

Let us know if this data was useful to you

Cansino Biologics's reported carbon emissions

In 2023, Cansino Biologics reported total greenhouse gas emissions of approximately 37,294,900 kg CO2e, with emissions distributed across various scopes: Scope 1 emissions totalled about 2,166,700 kg CO2e, Scope 2 emissions were approximately 14,064,580 kg CO2e, and Scope 3 emissions reached about 19,689,150 kg CO2e. This data reflects a comprehensive approach to emissions reporting, including both direct and indirect emissions. Cansino Biologics has set ambitious reduction targets, aiming for a 40% reduction in total greenhouse gas emissions per floor area by 2025, using 2021 as the baseline year. Furthermore, the company plans to achieve a 50% reduction by 2030 for both Scope 1 and Scope 2 emissions. These commitments demonstrate a proactive stance towards climate action and sustainability. The company’s emissions data is not cascaded from any parent organisation, indicating that it independently manages its climate commitments and reporting. Cansino Biologics is focused on enhancing its environmental performance while contributing to global climate goals.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20192020202120222023
Scope 1
4,609,750
0,000,000
0,000,000
0,000,000
0,000,000
Scope 2
10,386,950
00,000,000
00,000,000
0,000,000
00,000,000
Scope 3
-
-
-
00,000,000
00,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Cansino Biologics's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Cansino Biologics is in CN, which we do not have grid emissions data for.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Cansino Biologics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Beijing Institute of Biological Products Co., Ltd

CN
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Serum Institute of India Pvt. Ltd.

IN
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Sinovac Life Sciences Co., Ltd.

CN
Updated 14 days ago

Bharat Biotech Ltd.

IN
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

VBI Vaccines Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

AstraZeneca AB

SE
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250808.9
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy